Duration of immunogenicity of high-dose and prolonged-schedule hepatitis B vaccine among patients with chronic kidney disease: A one year follow-up study in China-Reference-Cited by-同舟云学术

Duration of immunogenicity of high-dose and prolonged-schedule hepatitis B vaccine among patients with chronic kidney disease: A one year follow-up study in China

Published:2022-08-18 Issue:11 Volume:21 Page:1675-1682
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Han Yujie¹²,Cao Na¹²,Lu Xiaoxiao¹²,Yao Tian²³,Shi Jing¹²,Wu Yuanting¹²,Dong Shuang¹,Shao Zhihong¹,Wang Jianmin⁴,Liu Hongting⁵,Guo Hongping⁶,Chai Guowei⁷,Liu Liming⁴,Wang Fuzhen⁸,Feng Yongliang¹²,Liang Xiaofeng⁹¹⁰¹¹,Wang Suping¹²

Affiliation:

1. School of Public Health, Shanxi Medical University, Taiyuan, China

2. Center of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University, Taiyuan, China

3. Department of Gastrointestinal Surgery, First Hospital of Shanxi Medical University, Taiyuan, China

4. Department of Nephrology, Linfen Central Hospital, Linfen, China

5. Department of Nephrology, Yuncheng Central Hospital, Yuncheng, China

6. Department of Nephrology, Linfen People’s Hospital, Linfen, China

7. Department of Nephrology, Houma People’s Hospital, Houma, China

8. National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China

9. Institute of Vaccine Industry, Jinan University, Guangzhou, China

10. Institute of Disease Control and Prevention, Jinan University, Guangzhou, China

11. Chinese Preventive Medicine Association, Beijing, China

Funder

National Science and Technology Major Project of the Ministry of Science and Technology of the People’s Republic of China

Key Research and Development Program of Science and Technology of Linfen

Key Research and Development Program of Lvliang

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2022.2112951

Reference41 articles.

1. Requirements for global elimination of hepatitis B: a modelling study

2. World Health Organization [Internet]. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. 2021 Jul. Available from: https://www.who.int/publications/i/item/9789240027077.

3. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

4. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China, 1992

5. Transforming our world: the 2030 agenda for sustainable development. United Nations General Assembly, Seventieth Session. New York, the United States of America; 2015 Sep 25s cited 2021 Apr 21. Available from: https://www.un.org/ga/search/view_doc.asp?symbol=A/RES/70/1&Lang=E